Skip to main content

A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-Mutant Melanoma Brain Metastasis

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Array BioPharma Inc

Start Date

October 31, 2019

End Date

June 29, 2021
 

Administered By

Duke Cancer Institute

Awarded By

Array BioPharma Inc

Start Date

October 31, 2019

End Date

June 29, 2021